Agilent Technologies A reported fourth-quarter fiscal 2024 earnings of $1.46 per share, which beat the Zacks Consensus Estimate by 3.6%. The figure increased 5.8% year over year.
Revenues of $1.70 billion surpassed the Zacks Consensus Estimate by 1.67%. The top line increased 0.8% on a reported basis and moved down 0.3% on a core basis from the year-ago quarter.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
This growth was driven by advancements in the Pharmaceutical, Diagnostics and Clinical sectors, along with improvements in the Chemical and Advanced Materials markets.
Agilent Technologies, Inc. Price, Consensus and EPS Surprise
Agilent Technologies, Inc. price-consensus-eps-surprise-chart | Agilent Technologies, Inc. Quote
However, the company faced challenges in the Food, Academic and Government, and Environmental and Forensics markets in the reported quarter.
Modest weakening conditions in the Americas and China region were significant headwinds, whereas growing momentum across Europe and the Asia Pacific provided a tailwind.
A's Segmental Top-Line Details
Agilent currently has three reporting segments -- Life Sciences & Applied Markets Group ("LSAG"), Agilent Cross Lab Group ("ACG"), and Diagnostics and Genomics Group ("DGG").
LSAG: The segment generated $833 million or 49% of the company's total revenues. This marked a 1% decline both on a reported and core basis compared with the prior-year quarter. This was due to softness in the instrument business as customers took a cautious approach toward capital expenditures. However, this was offset by strong demand for analytical lab consumables, which demonstrated mid-single-digit growth or better across all end markets and regions.
ACG: Revenues from the segment were $426 million, accounting for 25% of the total revenues. The top line grew 5% on a reported basis and 5% on a core basis compared with the prior-year quarter. This was driven by strong growth in contract business, including the fast-expanding Enterprise Services segment, which posted double-digit growth in the reported quarter. ACG achieved growth in all markets and regions except China, which was flat year over year but improved sequentially.
DGG: Revenues decreased 1% year over year on a reported and 3% on a core basis to $442 million, accounting for the remaining 26% of the total revenues. This was led by expected softness in Cell Analysis and NASD, partially offset by strong high-single-digit growth in the Cancer Dx business and improved results in Genomics.
The company recently unveiled a new organizational structure, aimed at accelerating its operational transformation and driving higher growth through a market-focused, customer-centric strategy. The new structure includes the Life Sciences and Diagnostics Markets Group (LDG), Applied Markets Group (AMG) and Agilent Cross Lab Group (ACG).
Agilent's Operating Results
For the fourth quarter of 2024, the gross margin in the LSAG segment contracted 40 basis points (bps) to 59.1% from the prior-year quarter. ACG's gross margin expanded 50 bps to 50.9%. DGG's gross margin contracted 220 bps year over year to 51.5%.
Research and development ("R&D") expenses on a non-GAAP basis were $109 million, down 6% from the prior-year quarter. Selling, general and administrative (SG&A) expenses on a non-GAAP basis rose slightly to $362 million, marking a 1.4% increase from the prior-year quarter.
As a percentage of revenues, R&D expenses fell 50 bps year over year to 6.4%, whereas SG&A expenses grew 10 bps year over year to 21.3%.
The non-GAAP operating margin of 27.4% for the fiscal fourth quarter of 2024 indicates a year-over-year contraction of 40 bps.
Segment-wise, the operating margin in the LSAG segment declined 60 bps to 28% from the prior-year quarter. ACG's operating margin fell 180 bps year over year to 32.6%. Meanwhile, the DGG's operating margin contracted 140 bps year over year to 21.3%.
A's Balance Sheet & Cash Flow
As of Oct. 31, 2024, Agilent's cash and cash equivalents were $1.33 billion, down from $1.78 billion as of July 31, 2024.
Accounts receivables were $1.32 billion at the end of the fourth quarter of fiscal 2024 compared with $1.23 billion at the end of the third quarter.
The long-term debt was $3.35 billion for the reported quarter compared with $2.14 billion in the prior quarter.
Cash flow from operating activities was $481 million in the fourth quarter of fiscal 2024 compared with $452 million in the previous quarter.
Agilent's Q1 Guidance
For the first quarter of fiscal 2025, management expects revenues of $1.650-$1.680 billion, indicating a decline of 0.5% against an increase of 1.3% on a reported basis and a decrease of 2% versus a rise of 0.2% on a core basis from the year-ago quarter's actuals. The Zacks Consensus Estimate for revenues is pegged at $1.69 billion.
Non-GAAP fiscal first-quarter earnings per share are expected to be $1.25-$1.28. The consensus mark for the same is pinned at $1.38 per share.
For fiscal 2025, management revised its revenue guidance from $6.45-$6.50 billion to $6.79-$6.87 billion, implying an increase of 4.3-5.5% on a reported basis and 2.5-3.5% on a core basis from the fiscal 2024 reported figure. The Zacks Consensus Estimate for the same is pegged at $6.83 billion.
The company also revised fiscal 2025 non-GAAP earnings per share guidance from $5.21-$5.25 to $5.54-$5.61. The consensus mark for fiscal 2024 earnings is pinned at $5.72 per share.
A's Zacks Rank & Stocks to Consider
Currently, Agilent carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader Zacks Computer and Technology sector are Audioeye AEYE, Cognizant Technology Solutions CTSH and Datadog DDOG, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Audioeye's shares have surged 388.6% in the year-to-date period. The long-term earnings growth rate for AEYE is estimated at 25%.
Cognizant Technology's shares have gained 6.8% in the year-to-date period. The long-term earnings growth rate for CTSH is anticipated to be 7.79%.
Datadog's shares have gained 29.1% in the year-to-date period. The long-term earnings growth rate for DDOG is expected to be 14.89%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report
Cognizant Technology Solutions Corporation (CTSH) : Free Stock Analysis Report
Agilent Technologies, Inc. (A) : Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.